Melane Sampson, Author at BioTuesdays

Developments

TriSalus launches trial evaluating pressure-enabled drug delivery in liver tumors

TriSalus Life Sciences (NASDAQ: TLSI) has initiated patient enrollment for its PREDICTT clinical trial designed to evaluate its novel Pressure-Enabled Drug Delivery (PEDD) approach in patients with primary or metastatic...

May 5, 2026

Executive Moves

Nancy Saitta and Leilani Bradford join Planet 13’s BoD

Planet 13 Holdings (CSE: PLTH; OTCQX: PLNH) has announced the appointments of the Honorable Nancy Saitta and Leilani Bradford as independent directors, filling two newly created seats on its board of directors (BoD)...

May 5, 2026

Feature

Adagio delivering first-of-its-kind innovation in cardiac ablation technology

Adagio Medical (NASDAQ: ADGM) is innovating catheter ablation technologies for the treatment of one of the most challenging and underserved areas in electrophysiology—ventricular tachycardia (VT), a dangerous type of...

May 5, 2026

Developments

JASN publishes analysis highlighting favorable outcomes from Akebia’s Phase 3 study

Akebia Therapeutics (NASDAQ: AKBA) has announced the publication of a post-hoc win statistics analysis of all-cause mortality and hospitalization from its global Phase 3 INNO2VATE program in the peer-reviewed Journal of...

May 4, 2026

Developments

InflaRx reports new data for izicopan in liver microsomes

InflaRx (NASDAQ: IFRX) has announced new preclinical data demonstrating low reactive metabolite formation of izicopan in human liver microsomes. Izicopan is an investigational, orally administered, small molecule...

May 4, 2026

Developments

Can-Fite reports positive data from study of namodenoson in pancreatic cancer

Can-Fite Biopharma (NYSE American: CANF; TASE: CANF) has announced positive clinical data from its Phase 2a study of namodenoson in patients with advanced pancreatic cancer. According to Can-Fite, the data from the...

April 30, 2026

Developments

Oncotelic moving closer to commercial launch of AI-enabled robotics

Oncotelic Therapeutics (OTCQB: OTLC) has announced an update on the advancement of its proprietary AI platform and robotic integration toward commercialization, following the integration of approximately 28 million...

April 30, 2026

Executive Moves

Piper Sandler adds Dr. Patrick McCormick to healthcare investment banking team

Investment bank, Piper Sandler, has announced the appointment of Patrick McCormick, MD, as a managing director in its healthcare investment banking group. Dr. McCormack will be based in San Francisco and focused on...

April 30, 2026

Executive Moves

Kunal Bhatia joins Strand as CFO

Closely held Strand Therapeutics has announced the appointment of Kunal Bhatia as chief financial officer (CFO). Mr. Bhatia brings 15 years of investment banking experience leading fundraising, business development, and...

April 30, 2026

Markets

Tivic rebrands as Valion Bio and changes ticker, closes down 28%

After changing its name from Tivic Health Systems (NASDAQ: TIVC) to Valion Bio (NASDAQ: VBIO), effective at market open today, the company’s stock price declined 28% to close at $1.01, after trading as low as $0.865...

April 28, 2026

Author - Melane Sampson

TriSalus launches trial evaluating pressure-enabled drug delivery in liver tumors

Nancy Saitta and Leilani Bradford join Planet 13’s BoD

Adagio delivering first-of-its-kind innovation in cardiac ablation technology

JASN publishes analysis highlighting favorable outcomes from Akebia’s Phase 3 study

InflaRx reports new data for izicopan in liver microsomes

Can-Fite reports positive data from study of namodenoson in pancreatic cancer

Oncotelic moving closer to commercial launch of AI-enabled robotics

Piper Sandler adds Dr. Patrick McCormick to healthcare investment banking team

Kunal Bhatia joins Strand as CFO

Tivic rebrands as Valion Bio and changes ticker, closes down 28%

Subscribe